4D Pharma (LON:DDDD)

4D Pharma (LON:DDDD)


Share Price
95.00 p
Change
1 (1.06 %)
Market Cap
£62.22 m
Proactive Investors - Run By Investors For Investors

4D Pharma RNS Release

Annual Report and Notice of AGM


RNS Number : 3674A
4d Pharma PLC
28 May 2019
 

 

4D pharma plc

(the "Company" or "4D")

Annual Report and Notice of AGM

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, announces that the Annual Report and Accounts for the year to 31 December 2018 and Notice of the Company's Annual General Meeting ("AGM") have been posted to shareholders.

An electronic copy of each of the Annual Report and Accounts and the Notice of AGM is available on the Company's website, www.4dpharmaplc.com.

The AGM will be held in the Chicago Room, Sofitel, Terminal 5, Wentworth Drive, London Heathrow Airport, Hounslow TW6 2GD, at 10 a.m. on Thursday 20 June 2019.


For further information please contact:

4D


Duncan Peyton, Chief Executive Officer

Fay Weston, Head of Investor Relations

 

+ 44 (0)113 895 0130

+ 44 (0)7990 381713

Zeus Capital Limited - Nomad and Joint Broker

+44 (0) 161 831 1512

Dan Bate / Jordan Warburton

 


Bryan Garnier & Co. Limited - Joint Broker

+44 (0)20 7332 2500

Dominic Wilson / Phil Walker


 

About 4D

Founded in February 2014, 4D is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.  4D has developed a proprietary platform that rationally identifies novel bacteria based on a deep understanding of function and mechanism.  4D's Live Biotherapeutic products are orally delivered single strains of bacteria that are naturally found in the healthy human gut.  4D has three clinical studies in progress, namely a Phase II clinical study of Blautix® in Irritable Bowel Syndrome, a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumours and a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours. Other focus programmes include disease areas such as asthma and CNS disease. 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ACSLLFSVETITFIA

4D Pharma Timeline

Newswire
June 10 2016

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use